-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Praxis Precision Medicine, Lowers Price Target to $650

Benzinga·06/02/2026 17:34:38
Listen to the news
Oppenheimer analyst Jay Olson maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and lowers the price target from $750 to $650.